Figure 7.

YTHDF1 links poor prognosis in HPSCC patients with CCT/RT treatments. (A) Quantification of YTHDF1 expression in cancerous and paired paracancerous tissues from patients in cohort 1 and cohort 2. (B) Representative IHC images of YTHDF and TFRC in HPSCC tissues from patients in cohort 1 and cohort 2. Scale bar = 100 µm (40 ×). (C) Pearson's rank correlation of YTHDF1 and TFRC proteins in HPSCC tissues from patients in cohort 1 and cohort 2 based on the IHC analysis. (D,E) Kaplan-Meier analysis of HPSCC patients to determine the correlations between YTHDF1 expression (D), TRFC expression (E) and recurrence-free survival based on data generated from IHC staining of HPSCC tissues. (F,G) Statistical analysis of the relative expression of TFRC (F) and serum ferritin (G) in HPSCC patients treated with or without CCT/RT, as assessed by the Mann-Whitney U test. (H,I) Kaplan-Meier analysis of HPSCC patients treated with CCT/RT to determine the correlations between YTHDF1 expression (H), TRFC expression (I) and recurrence-free survival. (J) Proposed model of the relationship between TFRC expression enhanced by the m⁶A modification reader YTHDF1, HPSCC cell progression, cell response to CCT/RT upon tumor hypoxia, and iron metabolism.